An interventional study of Neuclare in Dementia, Mild and Cognitive Disorder Mild, sponsored by Deepsonbio. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by Deepsonbio · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Dementia with a site in Korea, Republic of — 15 open to participants now, 18 under way, 4 of them phase 3. Dementia · Korea, Republic of.
Among the 52 studies in Dementia with a site in Korea, Republic of, this one is the 42nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2022, is one of 13 with no phase, and was the 32nd registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →15 of the 52 studies in Dementia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Chungnam National University · Sites in Korea, Republic of
Ages 19+
MapLight Therapeutics · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 55–90
GlaxoSmithKline · Sites in Korea, Republic of, United States, Argentina and 8 more countries
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Korea University · Sites in Korea, Republic of
Ages 60+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18 · Phase 4 3
First in 2003; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 220 across the 43 interventional studies, 163 across the 9 observational. Of the 28 that completed or were terminated, 8 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 52 have an industry lead sponsor. The 10 most frequent:
Deepsonbio is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Deepsonbio has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
5 of the studies in Dementia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT06664229Sunmi SongDevelopment of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults | 2026-12-31 |
| NCT07328386Hong JoonpioEffect of Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis in Patients With Intracranial Lymphatic Circulation Disorder | 2026-12-31 |
| NCT06088121Advanced Technology & CommunicationsStudy to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia | 2027-01-15 |
| NCT07485387Korea UniversityGlobal Collaborative Research on Establishing a Korean Cognitive Aging Cohort | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 52 studies in Dementia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.
Through methods such as Trail Making Test Black \& White, Attention Questionnaire Scale(AQS), Neuropsychiatric Inventory (NPI), etc, cognitive function improvement before and after using Neuclare will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient with mild cognitive disorder and early dementia who will be treated with the medical device-Neuclare
Device: Neuclare
It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
Change of Trail Making Test Black & White Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Trail Making Test Black \& White Score
Time frame: Week 5
Change of Attention Questionnaire Scale : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Attention Questionnaire Scale
Time frame: Week 5
Change of Neuropsychiatric Inventory Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Neuropsychiatric Inventory score
Time frame: Week 5
Change of Quality of life-AD Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Quality of life-AD Score
Time frame: Week 5
Change of MMSE-II Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by MMSE-II Score
Time frame: Week 5
change of beta-amyloid deposition measured by Amyloid PET-CT : From Baseline to Week 5
change of beta-amyloid deposition with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by Amyloid PET-CT
Time frame: Week 5
Change of glucose metabolic rate in brain measured by FDG PET-CT : From Baseline to Week 5
Compare glucose metabolic rate with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by FDG PET-CT
Time frame: Week 5
Change of Aβ oligomer density measured by MDS-OAβ test result : From Baseline to Week 5
Compare Aβ oligomer density with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by MDS-OAβ test
Time frame: Week 5
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Jul 2023, 9 months after the start.
Of 46 industry-sponsored interventional studies with no phase under Dementia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 9 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Deepsonbio